Holocene Advisors
ITCI

Holocene Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Holocene Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,198,298
Closed -$100M – 929
2024
Q4 		$100M Sell
1,198,298
-172,533
-13% -$14.2M 0.32% 88
2024
Q3 		$100M Sell
1,370,831
-108,844
-7% -$8.18M 0.41% 81
2024
Q2 		$101M Buy
1,479,675
+570,585
+63% +$39.6M 0.42% 77
2024
Q1 		$62.9M Sell
909,090
-352,767
-28% -$24.2M 0.23% 138
2023
Q4 		$90.4M Sell
1,261,857
-170,659
-12% -$9.82M 0.35% 100
2023
Q3 		$74.6M Sell
1,432,516
-263,292
-16% -$15.3M 0.33% 96
2023
Q2 		$107M Buy
1,695,808
+579,544
+52% +$36.1M 0.46% 74
2023
Q1 		$60.4M Sell
1,116,264
-614,829
-36% -$29.7M 0.3% 108
2022
Q4 		$91.6M Buy
1,731,093
+139,710
+9% +$7M 0.56% 61
2022
Q3 		$74M Sell
1,591,383
-36,025
-2% -$1.88M 0.47% 73
2022
Q2 		$92.9M Buy
1,627,408
+904,684
+125% +$51.3M 0.56% 55
2022
Q1 		$44.2M Buy
+722,724
New +$37.5M 0.23% 133

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Holocene Advisors's ITCI Position: Q1 2025 in Review

Holocene Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 1,198,298 shares — an estimated $100M sold.

Holocene Advisors first reported a position in ITCI in Q1 2022 and held it in 12 quarters. The position peaked at $107M in Q2 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Holocene Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Holocene Advisors sold 1,198,298 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $100M.
  • Holocene Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 12 quarters.
  • Holocene Advisors's Intra-Cellular Therapies Inc. position peaked at $107M in Q2 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Holocene Advisors's 13F filing for Q1 2025, filed 15 May 2025.